Therapeutic Asset Ratings

502 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Camizestrant Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
Camizestrant Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Carboplatin Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)
Datopotamab Deruxtecan Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)
Datopotamab Deruxtecan Advanced Solid Tumors That Are MTAP Deficient	AstraZeneca	P1/2	CCC (48)
Datopotamab Deruxtecan Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Durvalumab Breast Disorder	AstraZeneca	P1/2	CCC (48)
Durvalumab Ovarian Disorder	AstraZeneca	P1/2	CCC (48)
Durvalumab Solid Tumor Pediatric	AstraZeneca	P1/2	CCC (48)
Epirubicin Recurrent Anaplastic Large Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Hematopoietic And Lymphoid System Neoplasm	AstraZeneca	P1/2	CCC (48)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Solid Tumor Pediatric	AstraZeneca	P1/2	CCC (48)
Irinotecan Breast	AstraZeneca	P1/2	CCC (48)
Palacaparib Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
Pembrolizumab Anaplastic Large Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
Pembrolizumab Recurrent Anaplastic Large Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
Puxitatug Samrotecan Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
Puxitatug Samrotecan Squamous Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Rilvegostomig Skin Squamous Cell Carcinoma	AstraZeneca	P1/2	CCC (48)
Rilvegostomig Squamous Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)
Surovatamig B-Cell Acute Lymphoblastic Leukemia	AstraZeneca	P1/2	CCC (48)
Surovatamig Mantle Cell Lymphoma	AstraZeneca	P1/2	CCC (48)
T-Dxd Additional Indications Below for Module 4 and 5	AstraZeneca	P1/2	CCC (48)
T-Dxd Biliary Tract Cancer	AstraZeneca	P1/2	CCC (48)
T-Dxd Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (48)

Showing 201 to 225 of 502 assets

PreviousPage 9 of 21Next